{
  "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
  "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 57,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a dual-metric comparison (Hematologic Response vs. Cardiac Response) to highlight NXC-201's efficacy.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/13",
  "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
  "deckJsonHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3.json",
  "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "callout",
      "text": "NXC-201 Best Hematologic Response and Cardiac Response",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c6a3748-9836-4eac-afbf-35ce25d156cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.6,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "response rates in relapsed/refractory AL Amyloidosis",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55785d28-6424-4a9f-a748-5eeee6d5f114",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.7,
        "y": 0.3
      },
      "kind": "list",
      "text": "NXC-201 Only CAR-T in AL Amyloidosis; NXC-201 100% Overall Response Rate; Cardiac Response exceeds CAEL-101 and Birtamimab; Zero Neurotoxicity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a0f5c31-a88c-4b1d-a39d-df0760a2dccb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Birtamimab Source: Gertz MA et al. J Clin Oncol. 2016; CAEL-101 source: Edwards CV, et al. Blood. 2021...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fbfb5d4-8afd-413d-a5d4-96a436feda2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 - First CAR-T in AL Amyloidosis, a $6 billion market by 2025",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "522dfad9-bbdd-444e-bf25-f7eb132e81a9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "579a5079-1220-435b-82a2-57ddbae4481c",
      "evidence": "chart/bar-grouped: response rates in relapsed/refractory AL Amyloidosis",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "3d5fc5b2-ea8b-4465-aba5-e2eb4b774a08",
      "evidence": "Direct side-by-side performance comparison against competitors",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 16,
      "from": 11,
      "beatId": "0124f715-f9b4-4df7-a2f6-852908af15ae",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 11,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "db157f78-2fa5-4d70-8683-8c727b29e9dd",
      "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
      "position": 2,
      "objective": "How does NXC-201 perform in clinical trials?",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.8,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}